Hemophilia is officially classified as a rare disease. The Orphan Drug Act defines a rare disease as one affecting fewer than 200,000 people in the United States, and hemophilia falls well under that threshold. An estimated 33,000 males in the U.S. are living with the disorder, making it roughly six times rarer than the cutoff.
But “rare” doesn’t mean simple. Hemophilia varies widely in type, severity, and who it affects, and its impact on daily life and healthcare costs is disproportionately large for a condition with such a small patient population.
How Common Hemophilia Actually Is
Hemophilia A, the more common form caused by low levels of one clotting protein, occurs in about 1 in every 5,617 male births in the U.S. Hemophilia B, caused by a deficiency in a different clotting protein, is rarer still at 1 in every 19,283 male births. In terms of the existing population, that works out to roughly 12 cases of hemophilia A and 3.7 cases of hemophilia B per 100,000 U.S. males.
A third type, sometimes called hemophilia C, involves a different clotting factor entirely. It’s even less common, with global prevalence estimates ranging from 0.1 to about 246 per million people depending on the country and population studied. The United Kingdom reports the highest rates.
The National Organization for Rare Disorders (NORD) lists hemophilia in its rare disease database, and the FDA has approved multiple orphan drug therapies specifically for it. So by every formal measure, hemophilia qualifies as rare.
Severity Levels Shape the Experience
Not everyone with hemophilia experiences it the same way. The condition is classified into three levels based on how much clotting factor activity a person’s blood retains. Severe hemophilia means less than 1% of normal clotting activity, moderate means 1 to 5%, and mild means above 5% but below 40%. These categories matter because they determine how often spontaneous bleeding occurs, how early the condition is caught, and how aggressively it needs to be managed.
Severe hemophilia is typically diagnosed earliest. In a large French cohort study, the median age at diagnosis was about 6 months for severe cases, 9 months for moderate, and nearly 2.5 years for mild forms. When there’s already a brother with hemophilia in the family, testing often happens within the first two weeks of life. But more than half of all hemophilia cases arise with no family history, which can delay recognition.
Women Can Have Hemophilia Too
Hemophilia is traditionally described as a condition affecting males, since the genes responsible sit on the X chromosome. Males have only one copy, so a single mutation causes the disease. Females have two X chromosomes, so they’ve historically been called “carriers” rather than patients. That label is increasingly seen as a problem.
Among female carriers not specifically selected for bleeding symptoms, an estimated 28% have clotting factor levels below the threshold needed for normal clotting. In women and girls actually seen at specialized hemophilia treatment centers in the U.S., that number jumps to 52%. Many of these women experience real bleeding problems, including heavy menstrual periods, prolonged bleeding after surgery, and easy bruising. Medical organizations now recommend classifying women with low factor levels as having hemophilia, not just carrying it. This shift helps ensure they receive proper treatment and insurance coverage.
The Cost of a Rare Disease
Hemophilia’s rarity contributes directly to its extraordinary treatment costs. The primary therapy involves replacing the missing clotting factor through regular infusions, and these products are expensive to manufacture for a small patient population.
Total annual healthcare costs for a person with hemophilia A range from roughly $214,000 to $870,000, depending on severity and treatment type. For someone with severe hemophilia on a preventive infusion schedule, the average runs about $384,000 per year. Newer extended-acting products push costs even higher, ranging from $833,000 to over $1.1 million annually. A newer non-factor therapy approved for prevention of bleeding episodes costs around $358,000 per year. In March 2025, the FDA approved fitusiran, a treatment for both hemophilia A and B in patients 12 and older, expanding the options for people who develop resistance to standard clotting factor products.
A Global Gap in Diagnosis
The 33,000 figure in the U.S. reflects a country where nearly 100% of people with hemophilia get diagnosed. That’s not the global reality. In high-income countries, identification rates approach 100%, but in some low-income countries, fewer than 12% of people with hemophilia are ever diagnosed. Those unidentified patients often die prematurely from bleeding episodes that would be manageable with basic treatment.
Even among diagnosed patients worldwide, only about 35% receive the preventive therapy recommended by current treatment guidelines. The gap is largest in lower-income countries, where clotting factor products are either unavailable or unaffordable. According to data from the World Federation of Hemophilia’s global registry, the divide between wealthy and poor nations in hemophilia care remains one of the starkest inequities in rare disease medicine.
Why “Rare” Still Matters as a Label
The rare disease designation isn’t just a statistical label. It unlocks specific regulatory pathways that encourage drug companies to develop treatments for small patient populations. Without orphan drug incentives like tax credits and extended market exclusivity, the economics of developing therapies for 33,000 people in the U.S. would be even more challenging than they already are. Every gene therapy, extended-acting clotting factor, and novel treatment approach for hemophilia has benefited from the infrastructure built around the rare disease classification. For patients and families, the designation also connects them to specialized treatment centers, patient registries, and advocacy networks that wouldn’t exist for a condition seen as merely uncommon rather than officially rare.